CXCR4 and Miyoshi myopathy: Dosimetry and proof-of-concept for visualization of CXCR4-expression using 68Ga-pentixafor-PET has been demonstrated in MM patients in a pilot study allowing non-invasive detection of CXCR4 expression in 23/35 MM patients [38].